UTMD Q1 2023: NI +19.2% to $4.2M, EPS $1.16; OUS sales +23%; cash $80.9M

UTAH MEDICAL PRODUCTS INC

2023-Q1 EPS reported $1.16 revenue$12,520,000

Consolidated sales $12.5M, up 1.6% YoY; OUS sales up 23% (28% constant currency), domestic down 10%.
Operating income margin 35.5% (down from 36.7%) due to $348K higher litigation expenses.
Net income $4.2M, EPS $1.16 vs $0.96; NI margin 33.7% vs 28.7%.
Cash and investments $80.9M, up $5.9M from Dec 31, 2022; no debt.
Management reaffirms FY2023 objectives; regular quarterly dividend $0.295/share paid in Q1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.